Why GW Pharmaceuticals Dropped 14% In September презентация

medicine.
Sativex for multiple sclerosis spasticity is already approved in the EU.
Cannabidiol for schizophrenia phase 2 results were released September 15, but future development of this therapy is uncertain.
Cannabidiol results for treating epilepsy coming soon.
Shares dropped 14.1% in September.

various indications.
A study in evaluating THC (Sativex) in cancer pain failed to meet its endpoint earlier this year.
In September, results from a phase 2 study of CBD in schizophrenia failed to impress.
Failed to achieve statistical significance in primary endpoints.
Future development pathway unclear.
.

3 studies failed to outperform placebo.
Two other studies are underway.
One designed similarly to the failed trial was supposed to read-out results in Q2, but is now expected to read-out by year end.
A second study designed slightly differently was slated to read out by year end.

improvement on a key positive symptoms psychiatric scale at a rate that is greater than placebo.
Not statistically significant at improving cognition and responses on a negative symptoms scale.
Company shifting of endpoints increases skepticism.
Future plans may include pediatric research.

epilepsy.
Phase 3 trials underway for Epidiolex (CBD) in Dravet syndrome and Lennox-Gastaut syndrome.
Both are rare childhood diseases with a significant unmet need.
Trial results anticipated in Q1 2016.

lackluster this year.
Potential for multiple trial data in the next six months.
Likely to be binary events that could significantly affect shares.
This is a high risk/reward stock suitable only for speculative investors.
Avoid or underweight until positive efficacy results add conviction to medical marijuana thesis.

within Apple's famous design lab, and the company did everything in its power to keep its game changer a secret. But the secret is out, and best of all, our analysts have discovered a "roundabout way" to invest in the gadget... for just a fraction the price of AAPL stock....To see our free report on these stocks, just click here now.